Firmonertinib Shows Promise for Rare Lung Cancer Mutants

A new clinical study indicates high efficacy for firmonertinib in treating patients with metastatic EGFR PACC-mutant lung cancer.

Updated on Oct. 21, 2026 in Cancer

Isometric editorial illustration of a geometric molecular structure showing a side chain fitting into a protein receptor pocket. — The Phase Ib FURTHER study reports that firmonertinib shows significant efficacy in treating patients with metastatic EGFR PACC-mutant non-small cell lung cancer. AI Illustration. Upload story photo >

Live Poll

Do you believe targeting specific genetic mutations in cancer treatment will improve overall survival rates?

The Phase Ib FURTHER study reports positive outcomes for metastatic EGFR PACC-mutant non-small cell lung cancer (NSCLC) patients treated with firmonertinib. Results show strong objective response rates and progression-free survival across two daily dosage groups.

Why it matters

PACC mutations compress the ATP-binding pocket of the EGFR tyrosine kinase domain, which significantly restricts the effectiveness of conventional tyrosine kinase inhibitors. This study demonstrates a potential targeted therapeutic pathway for a mutation subset that remains difficult to treat with standard therapies.

In the FURTHER study, the 240 mg cohort achieved a 16.0-month median progression-free survival compared to 11.1 months for the 160 mg cohort. Additionally, patients showed a 47% intracranial objective response rate for asymptomatic brain metastases.

The players

The University of Texas MD Anderson Cancer Center

This institution provided the research leadership for the FURTHER study on EGFR PACC mutations.

The details

The treatment works by using a trifluoroethoxy side chain to improve contact points within the kinase domain of EGFR PACC mutants. Researchers observed complete molecular response in 80% of patients through plasma ctDNA clearance, though diarrhea was reported as the most common adverse event.

In 2021, researchers published a formal classification framework for EGFR mutations.
Researchers tracked study patients over a 16.5-month follow-up period.

Health Landscape

This study advances the treatment of PACC mutations, which account for 12% of total EGFR mutations, by overcoming the structural binding limitations found in conventional kinase inhibitors. It follows a pattern set by the upcoming Phase III ALPACCA trial, which will further validate the clinical utility of this drug compared to current standard-of-care treatments.

This trial highlights a promising new clinical option for patients with specific PACC-mutant lung cancer profiles that often respond poorly to current therapies. While the medication remains in the study phase, the potential for higher objective response rates offers a new avenue for physicians to consider when managing metastatic disease.

The takeaway

Targeted therapies continue to evolve as researchers identify more specific molecular subsets of non-small cell lung cancer. Patients and their caregivers should discuss emerging clinical trial options with oncologists to determine if newly discovered therapeutic pathways match their specific genetic profiles.

What happens next

The upcoming Phase III ALPACCA trial will compare firmonertinib directly with osimertinib or afatinib to establish its future role in treating patients with EGFR PACC mutations.